Expression and significance of Wnt signaling components and their target genes in breast carcinoma

Molecular Medicine Reports

Volumn 9, Issue 1, 2014, Pages 137-143

  He, Yanjiao ^a   Liu, Zhaoxia ^a   Qiao, Chao ^a   Xu, Miaosheng ^a   Yu, Jin ^a   Li, Guang ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

catenin; Axin; Breast neoplasmas; C myc; Cyclin D1; Wnt signaling

Indexed keywords

ADULT; AGED; AGED, 80 AND OVER; AXIN PROTEIN; BETA CATENIN; BREAST NEOPLASMS; CARCINOMA; CYCLIN D1; EXONS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MIDDLE AGED; MUTATION; PROTO-ONCOGENE PROTEINS C-MYC; WNT SIGNALING PATHWAY;

EID: 84893825795     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2013.1774     Document Type: Article

References (31)

1. Paul S and Dey A: Wnt signaling and cancer development: therapeutic implication. Neoplasma 55: 165-176, 2008.
2. Prosperi JR and Goss KH: A Wnt-ow of opportunity: targeting the Wnt/beta-catenin pathway in breast cancer. Curr Drug Targets 11: 1074-1088, 2010.
3. Miller JR: The Wnts. Genome Biol 3: 1-15, 2002.
4. Polakis P: Wnt signaling and cancer. Genes Dev 14: 1837-1851, 2000.
5. Lustig B and Behrens J: The Wnt signaling pathway and its role in tumor development. J Cancer Res Clin Oncol 129: 199-221, 2003.
6. Van Aken E, De Wever O, Correia da Rocha AS and Mareel M: Defective E-cadherin/catenin complexes in human cancer. Virchows Arch 439: 725-751, 2001.
7. Luo W and Lin SC: Axin: a master scaffold for multiple signaling pathways. Neurosignals 13: 99-113, 2004.
8. Böcker W: WHO classification of breast tumors and tumors of the female genital organs: pathology and genetics. Verh Dtsch Ges Pathol 86: 116-119, 2002 (In German).
9. Maruyama K, Ochiai A, Akimoto S, et al.: Cytoplasmic beta-catenin as a predictor of hematogenous metastasis in human colorectal cancer. Oncology 59: 302-309, 2000.
10. Nakajima M, Fukuchi M, Miyazaki T, et al.: Reduced expression of Axin correlates with tumour progression of oesophageal squamous cell carcinoma. Br J Cancer 88: 1734-1739, 2003.
11. Bankfalvi A, Terpe HJ, Breukelmann D, et al.: Immunophenotypic and prognostic analysis of E-cadherin and beta-catenin expression during breast carcinogenesis and tumour progression: a comparative study with CD44. Histopathology 34: 25-34, 1999.
12. Lin SY, Xia W, Wang JC, et al.: Beta-catenin a novel prognostic marker for breast cancer: its roles in cyclin D1 expression and cancer progression. Proc Natl Acad Sci USA 97: 4262-4266, 2000.
13. Lim SC and Lee MS: Significance of E-cadherin/beta-catenin complex and cyclin D1 in breast cancer. Oncol Rep 9: 915-928, 2002.
14. Dolled-Filhart M, McCabe A, Giltnane J, et al.: Quantitative in situ analysis of beta-catenin expression in breast cancer shows decreased expression is associated with poor outcome. Cancer Res 66: 5487-5494, 2006.
15. López-Knowles E, Zardawi SJ, McNeil CM, et al.: Cytoplasmic localization of beta-catenin is a marker of poor outcome in breast cancer patients. Cancer Epidemiol Biomarkers Prev 19: 301-309, 2010.
16. Chung GG, Zerkowski MP, Ocal IT, et al.: beta-Catenin and p53 analyses of a breast carcinoma tissue microarray. Cancer 100: 2084-2092, 2004.
17. Wang Z, Ren Y, He JJ, et al.: Relationship between ectopic expression of Wnt/beta-catenin signaling pathway and Her-2 overexpression in human breast carcinoma. J Xi'an Jiaotong Univ (Med Sci) 30: 587-591, 2009.
18. Kikuchi A: Tumor formation by genetic mutations in the components of the Wnt signaling pathway. Cancer Sci 94: 225-229, 2003.
19. He YJ, Jia XS, Qing SKZ, et al.: The study on p53 and beta-catenin gene mutations in NK/T cell lymphoma. Chin J Clin Oncol 31: 1385-1388, 2004.
20. Zhuang SM, Wiseman RW and Söderkvist P: Frequent mutations of the Trp53, Hras1 and beta-catenin (Catnb) genes in 1,3-butadiene-induced mammary adenocarcinomas in B6C3F1 mice. Oncogene 21: 5643-5648, 2002.
21. Howe LR and Brown AM: Wnt signaling and breast cancer. Cancer Biol Ther 3: 36-41, 2004.
22. Ozaki S, Ikeda S, Ishizaki Y, et al.: Alterations and correlations of the components in the Wnt signaling pathway and its target genes in breast cancer. Oncol Rep 14: 1437-1443, 2005.
23. Kizildag S, Zengel B, Vardar E, et al.: beta-catenin gene mutation in invasive ductal breast cancer. J BUON 13: 533-536, 2008.
24. Abraham SC, Rcynolds C, Lee JH, et al.: Fibromatosis of the breast and mutations involving the APC/beta-catenin pathway. Hum Pathol 33: 39-46, 2002.
25. Zeng L, Fagotto F, Zhang T, et al.: The mouse Fused locus encodes Axin, an inhibitor of the Wnt signaling pathway that regulates embryonic axis formation. Cell 90: 181-192, 1997.
26. Xu HT, Wang L, Lin D, et al.: Abnormal beta-catenin and reduced axin expression are associated with poor differentiation and progression in non-small cell lung cancer. Am J Clin Pathol 125: 534-541, 2006.
27. Ishizaki Y, Ikeda S, Fujimori M, et al.: Immunohistochemical analysis and mutational analyses of beta-catenin, Axin family and APC genes in hepatocellular carcinomas. Int J Oncol 24: 1077-1083, 2004.
28. Jin LH, Shao QJ, Luo W, et al.: Detection of point mutations of the Axin1 gene in colorectal cancers. Int J Cancer 107: 696-699, 2003.
29. Cong F, Varmus H: Nuclear-cytoplasmic shuttling of Axin regulates subcellular localization of beta-catenin. Proc Natl Acad Sci USA 101: 2882-2887, 2004.
30. Cliffe A, Hamada F, Bienz M: A role of Dishevelled in relocating Axin to the plasma membrane during wingless signaling. Curr Biol 13: 960-966, 2003.
31. Roh MS, Hong SH, Jeong JS, et al.: Gene expression profiling of breast cancer with emphasis of beta-catenin regulation. J Korean Med Sci 19: 275-282, 2004.